Anti-Human CD47 [B6H12] In Vivo Antibody - Low Endotoxin

(No reviews yet) Write a Review

제품 코드를 사용하여 Assay Genie 메인 사이트를 통해 주문합니다.

주문
SKU:
IVMB0313
Product Type:
In Vivo Monoclonal Antibody
Clone:
B6H12
Protein:
CD47
Isotype:
IgG1 k
Reactivity:
Human
Synonyms:
IAP
Synonyms:
OA3
Synonyms:
neutrophilin
Synonyms:
gp42
Synonyms:
MEM-133
Synonyms:
CDw149
Synonyms:
ITPG
Research Area:
Immunology
Endotoxin Level:
Low Endotoxin
Host Species:
Mouse
Applications:
FA
Applications:
FC
Applications:
In Vivo
Applications:
N
€0.00
Frequently bought together:

Description

Product Name:Anti-Human CD47 (Clone B6H12) In Vivo Antibody - Low Endotoxin
Product Code:IVMB0313
Size:1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:B6H12
Protein:CD47
Product Type:Monoclonal Antibody
Synonyms:IAP, OA3, neutrophilin, gp42, MEM-133, CDw149, ITPG
Isotype:IgG1 k
Reactivity:Human
Applications:FA, FC, In Vivo, N
Formulation:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Purity:≥95% monomer by analytical SEC ⋅ >95% by SDS Page
Product Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:FA, FC, In Vivo, N
Reactivity:Human
Host Species:Mouse
Specificity:Clone B6H12 recognizes an epitope on human CD47.
Antigen Distribution:CD47 is expressed on leukocytes, platelets, erythrocytes, epithelial cells, endothelial cells, fibroblasts, and is overexpressed in ovarian cancer, as well as many different tumor cells.
Immunogen:Purified Recombinant Human CD47 (>98%)
Concentration:1.0 - 5.0 mg/ml
Endotoxin Level:< 1.0 EU/mg as determined by the LAL method
Formulation:This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:≥95% monomer by analytical SEC ⋅ >95% by SDS Page
Preparation:Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:This Low Endotoxin Functional Formulation conjugate is stable when stored at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.

CD47 is a 50 kD transmembrane protein receptor to the Ig superfamily that can manifest in four isoforms, differing only in the length of their cytoplasmic tail. CD47 is involved in various cellular processes including apoptosis, proliferation, adhesion, and migration, and plays a key role in immune and angiogenic responses. CD47 was first identified as a tumor antigen on human ovarian cancer and its expression has subsequently been found on multiple human tumor types such as acute myeloid leukemia (AML), chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), non-Hodgkin’s lymphoma (NHL), multiple myeloma (MM), bladder cancer, and pediatric and adult brain tumors. CD47 interacts with membrane integrins, TSP-1, and SIRPα. The CD47/SIRPα interaction results in the inhibition of phagocytosis by macrophages thus, allowing cancer cells to multiply unchecked. Anti-CD47 antibody is a potential therapeutic target in a variety of cancers and for the treatment of pulmonary fibrosis. Anti-CD47 antibody treatment not only facilitates macrophage phagocytosis of cancer, but also promotes the activation of cancer-specific lymphocytes by acting as a beacon, flagging cancer cells which now display altered proteins to which the immune system can react.

Protein:CD47
Ligand/Receptor:Non-covalently associated with β3 integrins CD51/CD61, CD41/CD61. Thrombospondin is a ligand for CD47.
Research Area:Immunology
Shipping:2-8°C
PubMed:CD47
NCBI Gene Bank ID:961
UniProt:CD47
View AllClose

Related Products